Although biochemical assessment of several peptides is currently used in the clinic for the diagnosis and follow-up of NET patients, the use of general tumor markers such as chromogranin A (CgA) or neuron-specific enolase (NSE) is not recommended for screening nor are they sufficiently reliable as sole diagnostic procedures as they may be increased in several other oncological and non-oncological conditions [26]. The gene discussed is ENO2; the disease is neoplasm.